Jefferies Group’s Viking Therapeutics VKTX Stock Holding History

Jefferies Group’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1,627	Closed	-$10.8K	–	2064
2020 Q1	$8K	Sell	1,627 -52,500	-97%	-$323K	﹤0.01%	1970
2019 Q4	$434K	Sell	54,127 -7,470	-12%	-$54.5K	﹤0.01%	1901
2019 Q3	$424K	Buy	61,597 +6,986	+13%	+$51.9K	﹤0.01%	1973
2019 Q2	$453K	Buy	54,611 +23,139	+74%	+$198K	﹤0.01%	1715
2019 Q1	$313K	Sell	31,472 -23,002	-42%	-$193K	﹤0.01%	1781
2018 Q4	$417K	Buy	54,474 +49,889	+1,088%	+$596K	﹤0.01%	1528
2018 Q3	$80K	Buy	+4,585	New	+$54.6K	﹤0.01%	2243
2018 Q2	–	Sell	-20,300	Closed	-$135K	–	2704
2018 Q1	$89K	Buy	+20,300	New	+$112K	﹤0.01%	2082

Other funds holding VKTX

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Jefferies Group's VKTX Position: Q2 2020 in Review

Jefferies Group sold out of Viking Therapeutics (VKTX) in Q2 2020, closing a stake of 1,627 shares — an estimated $10.8K sold.

Jefferies Group first reported a position in VKTX in Q1 2018 and held it in 8 quarters. The position peaked at $453K in Q2 2019. 138 funds tracked by Wall St. Rank hold VKTX as of Q2 2020.

Jefferies Group reported no remaining Viking Therapeutics position as of Q2 2020 after selling out during the quarter.
Jefferies Group sold 1,627 Viking Therapeutics shares in Q2 2020, an estimated $10.8K.
Jefferies Group first reported a position in Viking Therapeutics in Q1 2018 and held it in 8 quarters.
Jefferies Group's Viking Therapeutics position peaked at $453K in Q2 2019.
138 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2020.

Based on Jefferies Group's 13F filing for Q2 2020, filed 14 Aug 2020.